hydralazine has been researched along with Chronic Disease in 105 studies
Hydralazine: A direct-acting vasodilator that is used as an antihypertensive agent.
hydralazine : The 1-hydrazino derivative of phthalazine; a direct-acting vasodilator that is used as an antihypertensive agent.
Chronic Disease: Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).
| Excerpt | Relevance | Reference |
|---|---|---|
| " placebo (H-HeFT) and 2) if metformin reduces the incidence of death, worsening heart failure, acute myocardial infarction, and stroke vs." | 9.41 | The DANish randomized, double-blind, placebo controlled trial in patients with chronic HEART failure (DANHEART): A 2 × 2 factorial trial of hydralazine-isosorbide dinitrate in patients with chronic heart failure (H-HeFT) and metformin in patients with chr ( Abdulla, J; Barasa, A; Bibby, BM; Bruun, NE; Brønnum-Schou, J; Bøtker, HE; Bøttcher, M; Dodt, K; Eiskjær, H; Gislason, G; Gustafsson, F; Hansen, VB; Hassager, C; Hollingdal, M; Høfsten, DE; Jonczy, B; Knudsen, AS; Kristensen, SL; Køber, L; Larsen, AH; Lomholdt, J; Madsen, JS; Mahboubi, K; Mellemkjær, S; Mikkelsen, KV; Møller, J; Nielsen, G; Nielsen, OW; Nørrelund, H; Poenaru, MP; Poulsen, MK; Raymond, I; Refsgaard, J; Schou, M; Serup-Hansen, K; Sillesen, K; Steffensen, FH; Torp-Petersen, C; Vraa, S; Wiggers, H, 2021) |
| "The similar two-year mortality in the hydralazine-isosorbide dinitrate arms in our previous Vasodilator-Heart Failure Trial (26 percent) and in the present trial (25 percent), as compared with that in the placebo arm in the previous trial, (34 percent) and the further survival benefit with enalapril in the present trial (18 percent) strengthen the conclusion that vasodilator therapy should be included in the standard treatment for heart failure." | 9.07 | A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. ( Cobb, F; Cohn, JN; Dunkman, WB; Francis, G; Johnson, G; Loeb, H; Smith, R; Tristani, F; Wong, M; Ziesche, S, 1991) |
| " Fifty patients with symptoms due to chronic heart failure despite diuretic therapy were randomised to receive additional treatment with either hydralazine or captopril." | 9.07 | Which vasodilator drug in patients with chronic heart failure? A randomised comparison of captopril and hydralazine. ( Brooks, NH; Lawrence, GP; Schofield, PM; Testa, HJ; Ward, C, 1991) |
| "Hydralazine (H) and nitrates (Ns), when combined, reduced morbidity and mortality in some trials of chronic heart failure (CHF)." | 8.91 | Hydralazine and nitrates alone or combined for the management of chronic heart failure: A systematic review. ( Clark, AL; Cleland, JG; Farag, M; Mabote, T; Nabhan, AF; Shoaib, A; Zhang, J, 2015) |
| "Nine male patients with stable chronic heart failure of different etiology and optimally treated with digoxine and diuretics were given hydralazine, 50 mg b." | 7.67 | Improved cardiac performance during exercise following hydralazine treatment in chronic heart failure. ( Conradson, TB; Rydén, L, 1984) |
| "In rats with large myocardial infarctions, we compared the effects of captopril, a presumed arterial and venous vasodilator, with hydralazine, which is thought primarily to be an arterial vasodilator." | 7.67 | Importance of venodilatation in prevention of left ventricular dilatation after chronic large myocardial infarction in rats: a comparison of captopril and hydralazine. ( Aguirre, M; Gay, RG; Goldman, S; Raya, TE, 1989) |
| "The comparative haemodynamic effects of oral prazosin hydrochloride and hydralazine were evaluated in 11 patients with chronic congestive heart failure." | 7.66 | Comparison of haemodynamic effects of oral hydralazine and prazosin hydrochloride in patients with chronic congestive heart failure. ( Arnold, S; Brundage, B; Chatterjee, K; Parmley, W; Ports, TA, 1979) |
| "Simultaneous hemodynamic and radionuclide angiographic assessment was made at rest and during exercise in nine patients with severe chronic congestive heart failure to determine the value of radionuclide left ventricular ejection fraction measurement in predicting the hemodynamic response to short-term treatment with oral hydralazine." | 7.66 | Hydralazine therapy in severe chronic heart failure: inability of radionuclide left ventricular ejection fraction measurement to predict the hemodynamic response. ( Franklin, BA; Goldberg, MJ; Kerin, NZ; Rubenfire, M; Ruskin, R; Willens, HJ, 1983) |
| "We studied the hemodynamic response to orally administered hydralazine (30 mg) and examined the changes in neurohumoral factors in 16 aged patients with chronic congestive heart failure." | 7.66 | Effect of orally administered hydralazine on neurohumoral factors and hemodynamic response in aged patients with chronic congestive heart failure. ( Kuwajima, I; Matsushita, S; Murakami, M; Sakai, M; Ueda, K, 1983) |
| "Several reports have suggested that because isosorbide dinitrate and hydralazine have different and additive haemodynamic effects at rest in patients with chronic heart failure, these agents should be administered in combination." | 7.66 | Vasodilator treatment with isosorbide dinitrate and hydralazine in chronic heart failure. ( Haughom, F; Kramer, B; Massie, BM; Shen, E, 1981) |
| "We studied the effect of vasodilator therapy on renal digoxin clearance in patients with chronic congestive heart failure." | 7.66 | Acute vasodilator therapy increases renal clearance of digoxin in patients with congestive heart failure. ( Benowitz, NL; Carlson, CJ; Cogan, JJ; Humphreys, MH; Rapaport, E, 1981) |
| "The haemodynamic effects of oral prazosin and hydralazine were evaluated in patients with refractory heart failure and compared with those of intravenous nitroprusside in the same patients." | 7.66 | Comparison of haemodynamic effects of oral prazosin, oral hydralazine, and intravenous nitroprusside in same patients with chronic heart failure. ( Conti, CR; Iacona, M; Mehta, J; Pepine, CJ, 1979) |
| "To examine the importance of left ventricular chamber size in determing the response to vasodilator therapy, we performed echocardiography in 40 patients with chronic refractory heart failure before they were treated with oral hydralazine." | 7.66 | Importance of left ventricular chamber size in determining the response to hydralazine in severe chronic heart failure. ( Gorlin, R; Herman, MV; Medina, N; Meller, J; Packer, M, 1980) |
| "The hemodynamic effects of oral hydralazine were investigated in ten patients (nine in NYHA Class IV and one in Class III) with chronic refractory heart failure." | 7.65 | Oral hydralazine therapy for chronic refractory heart failure. ( Chatterjee, K; Greenberg, B; Klausner, S; Massie, B; Norman, A; Parmley, WW; Werner, J, 1976) |
| "Congestive heart failure is accompanied by a number of compensatory mechanisms that may overshoot the mark." | 6.37 | Role of isosorbide dinitrate in management of chronic congestive heart failure. ( Parmley, WW, 1985) |
| " placebo (H-HeFT) and 2) if metformin reduces the incidence of death, worsening heart failure, acute myocardial infarction, and stroke vs." | 5.41 | The DANish randomized, double-blind, placebo controlled trial in patients with chronic HEART failure (DANHEART): A 2 × 2 factorial trial of hydralazine-isosorbide dinitrate in patients with chronic heart failure (H-HeFT) and metformin in patients with chr ( Abdulla, J; Barasa, A; Bibby, BM; Bruun, NE; Brønnum-Schou, J; Bøtker, HE; Bøttcher, M; Dodt, K; Eiskjær, H; Gislason, G; Gustafsson, F; Hansen, VB; Hassager, C; Hollingdal, M; Høfsten, DE; Jonczy, B; Knudsen, AS; Kristensen, SL; Køber, L; Larsen, AH; Lomholdt, J; Madsen, JS; Mahboubi, K; Mellemkjær, S; Mikkelsen, KV; Møller, J; Nielsen, G; Nielsen, OW; Nørrelund, H; Poenaru, MP; Poulsen, MK; Raymond, I; Refsgaard, J; Schou, M; Serup-Hansen, K; Sillesen, K; Steffensen, FH; Torp-Petersen, C; Vraa, S; Wiggers, H, 2021) |
| "Prudence is indicated in patients with congestive heart failure due to coronary artery disease." | 5.27 | A review of the long-term effects of prazosin and hydralazine in chronic congestive heart failure. ( Rutishauser, W, 1983) |
| "The similar two-year mortality in the hydralazine-isosorbide dinitrate arms in our previous Vasodilator-Heart Failure Trial (26 percent) and in the present trial (25 percent), as compared with that in the placebo arm in the previous trial, (34 percent) and the further survival benefit with enalapril in the present trial (18 percent) strengthen the conclusion that vasodilator therapy should be included in the standard treatment for heart failure." | 5.07 | A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. ( Cobb, F; Cohn, JN; Dunkman, WB; Francis, G; Johnson, G; Loeb, H; Smith, R; Tristani, F; Wong, M; Ziesche, S, 1991) |
| "We compared the effects of Hydralazine and Isosorbide dinitrate (ISDN) with those of an angiotensin-converting-enzyme inhibitor, captopril on mortality in patients with chronic congestive heart failure (NYHA class III and IV)." | 5.07 | Effect of vasodilator therapy on mortality in chronic congestive heart failure. ( Bhandari, B; Chakraborty, S; Ghose, JC; Mondal, M, 1993) |
| " Fifty patients with symptoms due to chronic heart failure despite diuretic therapy were randomised to receive additional treatment with either hydralazine or captopril." | 5.07 | Which vasodilator drug in patients with chronic heart failure? A randomised comparison of captopril and hydralazine. ( Brooks, NH; Lawrence, GP; Schofield, PM; Testa, HJ; Ward, C, 1991) |
| "Hydralazine (H) and nitrates (Ns), when combined, reduced morbidity and mortality in some trials of chronic heart failure (CHF)." | 4.91 | Hydralazine and nitrates alone or combined for the management of chronic heart failure: A systematic review. ( Clark, AL; Cleland, JG; Farag, M; Mabote, T; Nabhan, AF; Shoaib, A; Zhang, J, 2015) |
| " The American College of Obstetricians and Gynecologists recommends that acute-onset, severe hypertension be treated with first line-therapy (intravenous labetalol, intravenous hydralazine or oral nifedipine) within 60 minutes to reduce risk of maternal morbidity and death." | 3.96 | Identification of factors associated with delayed treatment of obstetric hypertensive emergencies. ( Akerman, MB; Elsayad, A; Halpern, TA; Heiselman, CJ; Heo, HJ; Kantorowska, A; Muscat, JC; Sicuranza, GB; Vintzileos, AM, 2020) |
| " One week after disease induction, animals were randomly assigned to chronic glomerulosclerosis, chronic glomerulosclerosis plus Bay 41-2272 (10 mg/kg body weight/day) or chronic glomerulosclerosis plus hydralazine (15 mg/kg body weight/day)." | 3.73 | Stimulation of soluble guanylate cyclase slows progression in anti-thy1-induced chronic glomerulosclerosis. ( Kawachi, H; Krämer, S; Kron, S; Loof, T; Martini, S; Neumayer, HH; Peters, H; Shimizu, F; Wang, Y, 2005) |
| "We evaluated long-term combined vasodilator therapy (hydralazine or ecarazine + isosorbide dinitrate) in 29 patients with chronic congestive heart failure resistant to the optimal conventional therapy." | 3.67 | Ambulatory long-term vasodilator therapy for chronic refractory heart failure: hemodynamic evaluation and clinical response. ( Hatano, M; Hibiya, K; Ichikawa, M; Nagasawa, M; Ozawa, Y; Saito, S; Tamura, Y; Tomobe, K; Yumikura, S, 1984) |
| "Dihydralazine, sold under the name of Nepressol, is the derivative of the hydrazinophthalazines used in France for the treatment of severe cardiac failure." | 3.67 | [Role of dihydralazine in the treatment of chronic cardiac insufficiency]. ( Baudouy, M; Camous, JP; Gibelin, P; Leborgne, L; Morand, P, 1985) |
| "In rats with large myocardial infarctions, we compared the effects of captopril, a presumed arterial and venous vasodilator, with hydralazine, which is thought primarily to be an arterial vasodilator." | 3.67 | Importance of venodilatation in prevention of left ventricular dilatation after chronic large myocardial infarction in rats: a comparison of captopril and hydralazine. ( Aguirre, M; Gay, RG; Goldman, S; Raya, TE, 1989) |
| "The effect of long-term vasodilator therapy (hydralazine, ecarazine or budralazine + isosorbide dinitrate) were evaluated for 20 patients with chronic congestive heart failure due to dilated cardiomyopathy (DCM) resistant to conventional therapy." | 3.67 | [Long-term vasodilator therapy of chronic refractory heart failure in patients with dilated cardiomyopathy]. ( Hatano, M; Hibiya, K; Kaseda, N; Moriuchi, M; Ozawa, Y; Saito, S; Tamura, Y; Tokutake, E; Tsuji, M; Yumikura, S, 1986) |
| "Nine male patients with stable chronic heart failure of different etiology and optimally treated with digoxine and diuretics were given hydralazine, 50 mg b." | 3.67 | Improved cardiac performance during exercise following hydralazine treatment in chronic heart failure. ( Conradson, TB; Rydén, L, 1984) |
| "The haemodynamic effects of oral prazosin and hydralazine were evaluated in patients with refractory heart failure and compared with those of intravenous nitroprusside in the same patients." | 3.66 | Comparison of haemodynamic effects of oral prazosin, oral hydralazine, and intravenous nitroprusside in same patients with chronic heart failure. ( Conti, CR; Iacona, M; Mehta, J; Pepine, CJ, 1979) |
| "To examine the importance of left ventricular chamber size in determing the response to vasodilator therapy, we performed echocardiography in 40 patients with chronic refractory heart failure before they were treated with oral hydralazine." | 3.66 | Importance of left ventricular chamber size in determining the response to hydralazine in severe chronic heart failure. ( Gorlin, R; Herman, MV; Medina, N; Meller, J; Packer, M, 1980) |
| "We studied the effect of vasodilator therapy on renal digoxin clearance in patients with chronic congestive heart failure." | 3.66 | Acute vasodilator therapy increases renal clearance of digoxin in patients with congestive heart failure. ( Benowitz, NL; Carlson, CJ; Cogan, JJ; Humphreys, MH; Rapaport, E, 1981) |
| "Several reports have suggested that because isosorbide dinitrate and hydralazine have different and additive haemodynamic effects at rest in patients with chronic heart failure, these agents should be administered in combination." | 3.66 | Vasodilator treatment with isosorbide dinitrate and hydralazine in chronic heart failure. ( Haughom, F; Kramer, B; Massie, BM; Shen, E, 1981) |
| "Simultaneous hemodynamic and radionuclide angiographic assessment was made at rest and during exercise in nine patients with severe chronic congestive heart failure to determine the value of radionuclide left ventricular ejection fraction measurement in predicting the hemodynamic response to short-term treatment with oral hydralazine." | 3.66 | Hydralazine therapy in severe chronic heart failure: inability of radionuclide left ventricular ejection fraction measurement to predict the hemodynamic response. ( Franklin, BA; Goldberg, MJ; Kerin, NZ; Rubenfire, M; Ruskin, R; Willens, HJ, 1983) |
| "We studied the hemodynamic response to orally administered hydralazine (30 mg) and examined the changes in neurohumoral factors in 16 aged patients with chronic congestive heart failure." | 3.66 | Effect of orally administered hydralazine on neurohumoral factors and hemodynamic response in aged patients with chronic congestive heart failure. ( Kuwajima, I; Matsushita, S; Murakami, M; Sakai, M; Ueda, K, 1983) |
| "In congestive heart failure, acute administration of the converting enzyme inhibitor captopril leads to a decrease in arterial pressure, systemic vascular resistance, left ventricular filling pressure, and the end-diastolic volumes of both ventricles, as well as to an increase in cardiac index, stroke volume index, right and left ventricular ejection fractions." | 3.66 | Converting-enzyme inhibitor therapy for chronic heart failure. ( Kramer, BL; Massie, BM; Topic, N, 1983) |
| " New drugs for the treatment of severe congestive heart failure include dopamine, which has a selective nonadrenergic dilator effect on the renal vascular bed, and dobutamine, which has potent inotropic effects, lowers the left ventricular filling pressure and does not increase the heart rate or the systemic vascular resistance." | 3.66 | Contributions of hemodynamic monitoring to the treatment of chronic congestive heart failure. ( Armstrong, PW, 1979) |
| "17 patients with severe chronic heart failure (class III and IV) were prescribed hydralazine, an arterial vasodilatator, orally at doses of 150 mg to 400 mg/day." | 3.66 | [Treatment of severe chronic cardiac insufficiency with dihydralazine. Short-and median-term results]. ( Alison, D; Latour, F; Lavigne, G; Masson, D; Morand, P, 1979) |
| "The comparative haemodynamic effects of oral prazosin hydrochloride and hydralazine were evaluated in 11 patients with chronic congestive heart failure." | 3.66 | Comparison of haemodynamic effects of oral hydralazine and prazosin hydrochloride in patients with chronic congestive heart failure. ( Arnold, S; Brundage, B; Chatterjee, K; Parmley, W; Ports, TA, 1979) |
| "A patient with severe, chronic congestive heart failure was unresponsive not only to conventional therapy, but also to nonparenteral nitroglycerin and isosorbide dinitrate; he became nitroprusside dependent." | 3.65 | Combination vasodilator therapy for severe chronic congestive heart failure. ( Chatterjee, K; Drew, D; Klausner, SC; Parmley, WW; Polansky, J; Zacherle, B, 1976) |
| "The hemodynamic effects of oral hydralazine were investigated in ten patients (nine in NYHA Class IV and one in Class III) with chronic refractory heart failure." | 3.65 | Oral hydralazine therapy for chronic refractory heart failure. ( Chatterjee, K; Greenberg, B; Klausner, S; Massie, B; Norman, A; Parmley, WW; Werner, J, 1976) |
| "Hydralazine-treated patients also had significant decreases in LV end-diastolic and end-systolic volume indexes, and a significant increase in ejection fraction." | 2.67 | Effects of long-term vasodilator therapy on electrocardiographic abnormalities in chronic aortic regurgitation. ( Bristow, JD; Cheitlin, M; Greenberg, B; Jacobson, N; Massie, B; Perlmutter, N; Siemienczuk, D; Szlachcic, J; Wilson, R, 1991) |
| "Congestive heart failure is accompanied by a number of compensatory mechanisms that may overshoot the mark." | 2.37 | Role of isosorbide dinitrate in management of chronic congestive heart failure. ( Parmley, WW, 1985) |
| "The effect on myocardial function and structure of long-term administration of quinapril (10-20 mg daily), an angiotensin-converting-enzyme (ACE) inhibitor, was investigated in 24 patients (18 men, 6 women; mean age 48 [20-65] years) with chronic isolated asymptomatic aortic or mitral regurgitation." | 1.29 | [Long-term treatment with quinapril in chronic aortic and mitral insufficiency]. ( Schömig, A; Schön, HR, 1995) |
| "In patients with congestive heart failure (CHF), overactivity of the sympathetic nervous system may be accompanied by an impairment of the baroreflex control mechanism." | 1.28 | Baroreceptor-mediated release of vasopressin in patients with chronic congestive heart failure and defective sympathetic responsiveness. ( Dietz, R; Kübler, W; Leinberger, H; Manthey, J; Opherk, D; Osterziel, KJ, 1992) |
| "Prudence is indicated in patients with congestive heart failure due to coronary artery disease." | 1.27 | A review of the long-term effects of prazosin and hydralazine in chronic congestive heart failure. ( Rutishauser, W, 1983) |
| "A total of 127 patients with bronchial asthma of infectious-allergic genesis and chronic obstructive bronchitis were examined for the central and regional hemodynamics as well as for the blood levels of serotonin and monoamine oxidase." | 1.27 | [Arterial hypertension in chronic bronchial obstruction and various problems of its treatment]. ( Bobrov, VA; Fushteĭ, IM; Ianushevskaia, TA; Polipova, SN, 1985) |
| "Symptomatic patients with chronic aortic regurgitation should undergo aortic valve replacement." | 1.27 | When to intervene in chronic aortic regurgitation. ( Gaasch, WH; Hoshino, PK, 1986) |
| "Propranolol was given to 10 hypertensive patients with CGN and hypotensive effect on renal function was observed." | 1.25 | Therapy and prognosis of hypertension in chronic nephritis. ( Kajiwara, N, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 77 (73.33) | 18.7374 |
| 1990's | 14 (13.33) | 18.2507 |
| 2000's | 6 (5.71) | 29.6817 |
| 2010's | 5 (4.76) | 24.3611 |
| 2020's | 3 (2.86) | 2.80 |
| Authors | Studies |
|---|---|
| Kantorowska, A | 1 |
| Heiselman, CJ | 1 |
| Halpern, TA | 1 |
| Akerman, MB | 1 |
| Elsayad, A | 1 |
| Muscat, JC | 1 |
| Sicuranza, GB | 1 |
| Vintzileos, AM | 1 |
| Heo, HJ | 1 |
| Li, Z | 1 |
| Lindner, DP | 1 |
| Bishop, NM | 1 |
| Cipolla, MJ | 1 |
| Wiggers, H | 1 |
| Køber, L | 1 |
| Gislason, G | 1 |
| Schou, M | 1 |
| Poulsen, MK | 1 |
| Vraa, S | 1 |
| Nielsen, OW | 1 |
| Bruun, NE | 1 |
| Nørrelund, H | 1 |
| Hollingdal, M | 1 |
| Barasa, A | 1 |
| Bøttcher, M | 1 |
| Dodt, K | 1 |
| Hansen, VB | 1 |
| Nielsen, G | 1 |
| Knudsen, AS | 1 |
| Lomholdt, J | 1 |
| Mikkelsen, KV | 1 |
| Jonczy, B | 1 |
| Brønnum-Schou, J | 1 |
| Poenaru, MP | 1 |
| Abdulla, J | 1 |
| Raymond, I | 1 |
| Mahboubi, K | 1 |
| Sillesen, K | 1 |
| Serup-Hansen, K | 1 |
| Madsen, JS | 1 |
| Kristensen, SL | 1 |
| Larsen, AH | 1 |
| Bøtker, HE | 1 |
| Torp-Petersen, C | 1 |
| Eiskjær, H | 1 |
| Møller, J | 1 |
| Hassager, C | 1 |
| Steffensen, FH | 1 |
| Bibby, BM | 1 |
| Refsgaard, J | 1 |
| Høfsten, DE | 1 |
| Mellemkjær, S | 1 |
| Gustafsson, F | 1 |
| Leavitt, K | 1 |
| Običan, S | 1 |
| Yankowitz, J | 1 |
| Lim, WY | 1 |
| Woldman, S | 1 |
| Farag, M | 1 |
| Mabote, T | 1 |
| Shoaib, A | 1 |
| Zhang, J | 1 |
| Nabhan, AF | 1 |
| Clark, AL | 1 |
| Cleland, JG | 1 |
| Olson-Chen, C | 1 |
| Seligman, NS | 1 |
| Leelahavanichkul, A | 1 |
| Yan, Q | 1 |
| Hu, X | 1 |
| Eisner, C | 1 |
| Huang, Y | 1 |
| Chen, R | 1 |
| Mizel, D | 1 |
| Zhou, H | 1 |
| Wright, EC | 1 |
| Kopp, JB | 1 |
| Schnermann, J | 1 |
| Yuen, PS | 1 |
| Star, RA | 1 |
| Ahmed, A | 1 |
| Anker, SD | 1 |
| Negassa, A | 1 |
| Coats, AJ | 1 |
| Afzal, R | 1 |
| Poole-Wilson, PA | 1 |
| Cohn, JN | 2 |
| Yusuf, S | 1 |
| Massie, BM | 5 |
| Wang, Y | 1 |
| Krämer, S | 1 |
| Loof, T | 1 |
| Martini, S | 1 |
| Kron, S | 1 |
| Kawachi, H | 1 |
| Shimizu, F | 1 |
| Neumayer, HH | 1 |
| Peters, H | 1 |
| Crouch, MA | 1 |
| Rosen, D | 1 |
| Decaro, MV | 1 |
| Graham, MG | 1 |
| Opie, LH | 1 |
| Novikov, SV | 1 |
| Mareev, VIu | 1 |
| Artese, D | 1 |
| Albani, A | 1 |
| Di Tomasso, E | 1 |
| Mason, DT | 2 |
| Awan, NA | 1 |
| Joye, JA | 1 |
| Lee, G | 1 |
| DeMaria, AN | 1 |
| Amsterdam, EA | 1 |
| Goldberg, MJ | 1 |
| Franklin, BA | 1 |
| Rubenfire, M | 1 |
| Kerin, NZ | 1 |
| Willens, HJ | 1 |
| Ruskin, R | 1 |
| Kramer, BL | 1 |
| Topic, N | 1 |
| Schwartz, AB | 1 |
| Chatterjee, K | 7 |
| Ueda, K | 1 |
| Sakai, M | 1 |
| Matsushita, S | 1 |
| Kuwajima, I | 1 |
| Murakami, M | 1 |
| Satinsky, JD | 1 |
| Saito, S | 2 |
| Ichikawa, M | 1 |
| Ozawa, Y | 2 |
| Yumikura, S | 2 |
| Nagasawa, M | 1 |
| Hibiya, K | 2 |
| Tamura, Y | 2 |
| Tomobe, K | 1 |
| Hatano, M | 2 |
| Magorien, RD | 1 |
| Unverferth, DV | 1 |
| Leier, CV | 1 |
| Reifart, N | 1 |
| Kaltenbach, M | 1 |
| Bussmann, WD | 1 |
| Conradson, TB | 2 |
| Rydén, L | 2 |
| Kothiala, A | 1 |
| Ramnani, K | 1 |
| Patel, HR | 2 |
| Mehta, NC | 2 |
| Shah, CP | 2 |
| Eninia, GI | 1 |
| Smeltere, ES | 1 |
| Godlevska, MA | 1 |
| Uzulinia, IP | 1 |
| Ke, YN | 2 |
| Parmley, WW | 4 |
| Rutishauser, W | 1 |
| Kittleson, MD | 2 |
| Eyster, GE | 2 |
| Olivier, NB | 1 |
| Anderson, LK | 1 |
| Shvedenko, LA | 1 |
| Parashchak, AP | 1 |
| Iurkevich, ST | 1 |
| Neporadnyĭ, MD | 1 |
| Bigar', PV | 1 |
| Fried, R | 1 |
| Steinherz, LJ | 1 |
| Levin, AR | 1 |
| Linday, L | 1 |
| Tan, CT | 1 |
| Miller, D | 1 |
| Rouleau, JL | 1 |
| Berkowitz, RL | 2 |
| Packer, M | 4 |
| Meller, J | 4 |
| Medina, N | 3 |
| Yushak, M | 1 |
| Gorlin, R | 3 |
| Kramer, B | 1 |
| Shen, E | 1 |
| Haughom, F | 1 |
| Cogan, JJ | 1 |
| Humphreys, MH | 1 |
| Carlson, CJ | 1 |
| Benowitz, NL | 1 |
| Rapaport, E | 1 |
| Herman, MV | 2 |
| Cabaniss, CD | 1 |
| Greenberg, BH | 2 |
| DeMots, H | 1 |
| Murphy, E | 1 |
| Rahimtoola, S | 1 |
| Francoual, M | 1 |
| Nitenberg, A | 1 |
| Ginks, WR | 1 |
| Redwood, DR | 1 |
| Schön, HR | 1 |
| Schömig, A | 1 |
| Volkova, LI | 1 |
| Shteĭngart, IuN | 1 |
| Lin, M | 1 |
| Chiang, HT | 1 |
| Lin, SL | 1 |
| Chang, MS | 1 |
| Chiang, BN | 1 |
| Kuo, HW | 1 |
| Cheitlin, MD | 1 |
| Corbalán, R | 2 |
| Kunstmann, S | 1 |
| Jalil, J | 2 |
| Ghose, JC | 1 |
| Chakraborty, S | 1 |
| Mondal, M | 1 |
| Bhandari, B | 1 |
| Roth, A | 1 |
| Shotan, A | 1 |
| Elkayam, U | 1 |
| Knowlen, GG | 1 |
| Nachreiner, RF | 1 |
| Massie, B | 3 |
| Rubin, S | 1 |
| Gelberg, H | 1 |
| Brundage, BH | 1 |
| Ports, TA | 2 |
| Morand, P | 3 |
| Lavigne, G | 2 |
| Masson, D | 2 |
| Latour, F | 2 |
| Alison, D | 1 |
| Page, A | 1 |
| Larnaudie, B | 1 |
| Pic, A | 1 |
| Videau, P | 1 |
| Besse, P | 1 |
| Lloyd, EA | 1 |
| Curet, LB | 1 |
| Olson, RW | 1 |
| Arias, F | 1 |
| Zamora, J | 1 |
| Armstrong, PW | 1 |
| Arnold, S | 1 |
| Brundage, B | 1 |
| Parmley, W | 1 |
| Mehta, J | 1 |
| Iacona, M | 1 |
| Pepine, CJ | 1 |
| Conti, CR | 1 |
| Velasco, M | 1 |
| Guevara, J | 1 |
| Urbina-Quintana, A | 1 |
| Hernández-Pieretti, O | 1 |
| Koch-Weser, J | 1 |
| Drew, D | 1 |
| Klausner, SC | 1 |
| Polansky, J | 1 |
| Zacherle, B | 1 |
| Greenberg, B | 2 |
| Werner, J | 1 |
| Klausner, S | 1 |
| Norman, A | 1 |
| Kajiwara, N | 1 |
| Woods, JR | 1 |
| Brinkman, CR | 1 |
| Baumbach, GL | 1 |
| Heistad, DD | 1 |
| Manthey, J | 1 |
| Dietz, R | 1 |
| Opherk, D | 1 |
| Osterziel, KJ | 1 |
| Leinberger, H | 1 |
| Kübler, W | 1 |
| Wilson, R | 1 |
| Perlmutter, N | 1 |
| Jacobson, N | 1 |
| Siemienczuk, D | 1 |
| Szlachcic, J | 1 |
| Bristow, JD | 1 |
| Cheitlin, M | 1 |
| Haeusslein, EA | 1 |
| Schofield, PM | 1 |
| Brooks, NH | 1 |
| Lawrence, GP | 1 |
| Testa, HJ | 1 |
| Ward, C | 1 |
| Johnson, G | 1 |
| Ziesche, S | 1 |
| Cobb, F | 1 |
| Francis, G | 1 |
| Tristani, F | 1 |
| Smith, R | 1 |
| Dunkman, WB | 1 |
| Loeb, H | 1 |
| Wong, M | 1 |
| Zhilin, SV | 1 |
| Vorob'ev, BI | 1 |
| Kastanaian, AA | 1 |
| Masalitinova, IV | 1 |
| Rahimtoola, SH | 1 |
| Raya, TE | 1 |
| Gay, RG | 1 |
| Aguirre, M | 1 |
| Goldman, S | 1 |
| Chervenak, FA | 1 |
| Dékány, M | 1 |
| Bányai, F | 1 |
| Antalóczy, Z | 1 |
| Moriuchi, M | 1 |
| Kaseda, N | 1 |
| Tsuji, M | 1 |
| Tokutake, E | 1 |
| Gavrisiuk, VK | 2 |
| Iakhnitsa, TV | 2 |
| Feshchenko, IuI | 1 |
| Roschlau, G | 1 |
| Hass, S | 1 |
| Schmehl, V | 1 |
| Kirichenko, LL | 1 |
| Gaĭdukova, NI | 1 |
| Solov'eva, FV | 1 |
| Thorat, PB | 1 |
| Patel, KH | 1 |
| Bobrov, VA | 2 |
| Fushteĭ, IM | 2 |
| Polivoda, SN | 1 |
| Arriagada, D | 1 |
| Rodríguez, JA | 1 |
| Chamorro, G | 1 |
| Meleda, I | 1 |
| Casanegra, P | 1 |
| Valenzuela, P | 1 |
| Polipova, SN | 1 |
| Ianushevskaia, TA | 1 |
| Escobar, E | 1 |
| Thumala, A | 1 |
| Domenech, R | 1 |
| Venegas, P | 1 |
| Hoshino, PK | 1 |
| Gaasch, WH | 1 |
| Geggel, RL | 1 |
| Dozor, AJ | 1 |
| Fyler, DC | 1 |
| Reid, LM | 1 |
| Krzyś, T | 1 |
| Kalawski, R | 1 |
| Flaczyński, K | 1 |
| Lenartowicz, I | 1 |
| Baudouy, M | 1 |
| Camous, JP | 1 |
| Gibelin, P | 1 |
| Leborgne, L | 1 |
| Maas, D | 1 |
| Gilmore, HR | 1 |
| Loggie, JM | 1 |
| Ayers, CR | 1 |
| Harris, RH | 1 |
| Lefer, LG | 1 |
| Vertes, V | 1 |
| Cangiano, JL | 1 |
| Berman, LB | 1 |
| Gould, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Double-blind, Placebo Controlled Study (DANHEART): Hydralazine-ISDN in Patients With Chronic Heart Failure - Hydralazine Heart Failure Trial (H-HeFT) and Metformin in Patients With Chronic Heart Failure and Diabetes or Insulin Resistance - M[NCT03514108] | Phase 4 | 1,500 participants (Anticipated) | Interventional | 2018-03-01 | Recruiting | ||
| Innovative Strategies for Implementing New CHF Guideline Recommendations[NCT00012974] | Phase 1/Phase 2 | 60 participants (Anticipated) | Interventional | 2005-11-30 | Completed | ||
| Regional and Systemic Hemodynamic Effects of a Long-term Administration of Amlodipine in Patients With Chronic Heart Failure Treated With a Combination of Enalapril, Furosemide and Digoxin[NCT00151619] | Phase 2 | 7 participants (Actual) | Interventional | 1999-02-10 | Terminated | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
22 reviews available for hydralazine and Chronic Disease
| Article | Year |
|---|---|
Treatment and Prevention of Hypertensive Disorders During Pregnancy.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Aspirin; Calcium Channel Blockers; Chronic Dis | 2019 |
Pharmacological management of chronic heart failure: old drugs, new drugs and new indications.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibit | 2013 |
Hydralazine and nitrates alone or combined for the management of chronic heart failure: A systematic review.
Topics: Chronic Disease; Drug Therapy, Combination; Heart Failure; Humans; Hydralazine; Mortality; Nitrates; | 2015 |
Hypertensive Emergencies in Pregnancy.
Topics: Antihypertensive Agents; Cesarean Section; Chronic Disease; Congenital Abnormalities; Emergencies; E | 2016 |
Pharmacotherapy implications of revised chronic heart failure guidelines.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme | 2006 |
Evidence-based treatment of chronic heart failure.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme | 2007 |
[Adrenergic alpha-receptor blockaders and direct arteriolar vasodilators in treatment of chronic cardiac insufficiency].
Topics: Adrenergic alpha-Antagonists; Arterioles; Cardiac Output, Low; Chronic Disease; Hemodynamics; Humans | 1983 |
Vasodilator therapy in chronic congestive heart failure.
Topics: Captopril; Chronic Disease; Drug Therapy, Combination; Heart Failure; Hemodynamics; Humans; Hydralaz | 1983 |
Vasodilator therapy for chronic heart failure.
Topics: Captopril; Chronic Disease; Heart Failure; Hemodynamics; Humans; Hydralazine; Nitrates; Nitroglyceri | 1980 |
Anti-hypertensive drugs in the pregnant patient.
Topics: Antihypertensive Agents; Chronic Disease; Clonidine; Diazoxide; Diuretics; Female; Fetus; Furosemide | 1980 |
[Vasodilator agents in chronic heart failure: which is the best option?].
Topics: Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Clinical Trials as Topic; Drug Therapy, C | 1993 |
Afterload reduction and cardiac performance. Physiologic basis of systemic vasodilators as a new approach in treatment of congestive heart failure.
Topics: Aorta; Cardiac Output; Chronic Disease; Heart; Heart Failure; Heart Ventricles; Hemodynamics; Humans | 1978 |
The use of vasodilator agents in the treatment of heart failure.
Topics: Cardiac Output; Cardiomegaly; Catheterization; Chronic Disease; Coronary Vessels; Dose-Response Rela | 1979 |
Oral vasodilator therapy for chronic heart failure: a plea for caution.
Topics: Cardiac Output; Chronic Disease; Forecasting; Heart Failure; Humans; Hydralazine; Nitrates; Prazosin | 1978 |
Drug therapy. Hydralazine.
Topics: Antibodies, Antinuclear; Arthritis, Rheumatoid; Blood Pressure; Cardiac Output; Chronic Disease; Dru | 1976 |
Drug-induced changes in mechanics and structure of cerebral arterioles.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Arterioles; Brain; Chronic Disease; Compliance; H | 1992 |
Vasodilator therapy in chronic severe aortic regurgitation.
Topics: Aortic Valve Insufficiency; Chronic Disease; Digitalis Glycosides; Echocardiography; Hemodynamics; H | 1990 |
Hypertension in pregnancy.
Topics: Adrenergic beta-Antagonists; Animals; Chronic Disease; Clonidine; Diuretics; Female; Humans; Hydrala | 1985 |
Role of isosorbide dinitrate in management of chronic congestive heart failure.
Topics: Administration, Oral; Chronic Disease; Drug Administration Schedule; Drug Therapy, Combination; Drug | 1985 |
[Antinuclear factors. Demonstration and clinico-diagnostic significance].
Topics: Antibodies, Antinuclear; Arthritis, Rheumatoid; Autoantibodies; Autoimmune Diseases; Chronic Disease | 1969 |
The treatment of chronic hypertension.
Topics: Adult; Blood Pressure Determination; Chronic Disease; Diuretics; Female; Ganglionic Blockers; Guanet | 1971 |
Hypertension in children and adolescents. II. Drug therapy.
Topics: Age Factors; Antihypertensive Agents; Blood Pressure Determination; Child; Chlorothiazide; Chronic D | 1969 |
11 trials available for hydralazine and Chronic Disease
| Article | Year |
|---|---|
The DANish randomized, double-blind, placebo controlled trial in patients with chronic HEART failure (DANHEART): A 2 × 2 factorial trial of hydralazine-isosorbide dinitrate in patients with chronic heart failure (H-HeFT) and metformin in patients with chr
Topics: Aged; Chronic Disease; Denmark; Diabetes Mellitus; Double-Blind Method; Drug Combinations; Female; H | 2021 |
Hydralazine therapy in chronic congestive heart failure. Sustained central and regional hemodynamic responses.
Topics: Administration, Oral; Cardiac Output; Chronic Disease; Clinical Trials as Topic; Double-Blind Method | 1984 |
Loss of effectiveness of dihydralazine in the long-term treatment of chronic heart failure.
Topics: Adult; Aged; Cardiac Output; Chronic Disease; Coronary Circulation; Coronary Disease; Dihydralazine; | 1984 |
Vasodilator therapy in chronic asymptomatic aortic regurgitation: enalapril versus hydralazine therapy.
Topics: Aged; Aortic Valve Insufficiency; Chronic Disease; Double-Blind Method; Echocardiography; Enalapril; | 1994 |
Effect of vasodilator therapy on mortality in chronic congestive heart failure.
Topics: Adult; Aged; Captopril; Chi-Square Distribution; Chronic Disease; Double-Blind Method; Drug Therapy, | 1993 |
A randomized comparison between the hemodynamic effects of hydralazine and nitroglycerin alone and in combination at rest and during isometric exercise in patients with chronic mitral regurgitation.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Chronic Disease; Drug Therapy, Combination; Exercise; | 1993 |
Effects of long-term vasodilator therapy on electrocardiographic abnormalities in chronic aortic regurgitation.
Topics: Adult; Aortic Valve Insufficiency; Cardiac Volume; Chronic Disease; Double-Blind Method; Electrocard | 1991 |
Which vasodilator drug in patients with chronic heart failure? A randomised comparison of captopril and hydralazine.
Topics: Adult; Aged; Captopril; Cardiomyopathy, Dilated; Chronic Disease; Coronary Disease; Exercise Test; F | 1991 |
A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure.
Topics: Adolescent; Adult; Aged; Chronic Disease; Death, Sudden; Double-Blind Method; Drug Administration Sc | 1991 |
[Differential use of peripheral vasodilators in the treatment of chronic circulatory failure in patients with mitral valve insufficiency].
Topics: Adult; Chronic Disease; Clinical Trials as Topic; Heart Failure; Hemodynamics; Humans; Hydralazine; | 1990 |
Comparative study on the short-term effects of angiotensin converting enzyme inhibitors (Lopirin, SQUIBB and Tensiomin), and dihydralazine in chronic cardiac failure.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Captopril; Cardiac Output, Lo | 1988 |
72 other studies available for hydralazine and Chronic Disease
| Article | Year |
|---|---|
Identification of factors associated with delayed treatment of obstetric hypertensive emergencies.
Topics: Administration, Intravenous; Administration, Oral; Adult; After-Hours Care; Antihypertensive Agents; | 2020 |
ACE (Angiotensin-Converting Enzyme) Inhibition Reverses Vasoconstriction and Impaired Dilation of Pial Collaterals in Chronic Hypertension.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimidazoles; Biphenyl Compound | 2020 |
Angiotensin II overcomes strain-dependent resistance of rapid CKD progression in a new remnant kidney mouse model.
Topics: Albuminuria; Anemia; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertens | 2010 |
American College of Cardiology/American Heart Association Chronic Heart Failure Evaluation and Management guidelines: relevance to the geriatric practice.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Echoca | 2003 |
Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Data Interpretation, Statistical; D | 2003 |
The year in heart failure: 2004.
Topics: Adrenergic beta-Antagonists; Anti-Inflammatory Agents, Non-Steroidal; Chronic Disease; Defibrillator | 2005 |
Stimulation of soluble guanylate cyclase slows progression in anti-thy1-induced chronic glomerulosclerosis.
Topics: Animals; Biomarkers; Blood Pressure; Body Weight; Chronic Disease; Disease Progression; Eating; Enzy | 2005 |
Drugs and the heart. VI. Vasodilating drugs.
Topics: Cardiotonic Agents; Chronic Disease; Heart Failure; Hemodynamics; Humans; Hydralazine; Hypertension; | 1980 |
[Vasodilator drugs in the therapy of chronic congestive heart failure. Clinico-case contribution].
Topics: Blood Pressure; Cardiomegaly; Chronic Disease; Drug Evaluation; Heart; Heart Failure; Humans; Hydral | 1983 |
Treatment of acute and chronic congestive heart failure by vasodilator-afterload reduction.
Topics: Acute Disease; Antihypertensive Agents; Blood Pressure; Cardiac Output; Chronic Disease; Diastole; H | 1980 |
Hydralazine therapy in severe chronic heart failure: inability of radionuclide left ventricular ejection fraction measurement to predict the hemodynamic response.
Topics: Adult; Aged; Cardiac Catheterization; Cardiac Output; Chronic Disease; Drug Evaluation; Female; Hear | 1983 |
Converting-enzyme inhibitor therapy for chronic heart failure.
Topics: Captopril; Chronic Disease; Double-Blind Method; Drug Therapy, Combination; Exercise Test; Heart Fai | 1983 |
Effect of orally administered hydralazine on neurohumoral factors and hemodynamic response in aged patients with chronic congestive heart failure.
Topics: Administration, Oral; Aged; Aldosterone; Chronic Disease; Epinephrine; Female; Heart Failure; Hemody | 1983 |
Chronic heart failure in the elderly: vasodilator therapy.
Topics: Aged; Blood Pressure; Chronic Disease; Female; Follow-Up Studies; Heart Failure; Humans; Hydralazine | 1983 |
Ambulatory long-term vasodilator therapy for chronic refractory heart failure: hemodynamic evaluation and clinical response.
Topics: Adult; Aged; Ambulatory Care; Cardiac Catheterization; Cardiomyopathy, Dilated; Chronic Disease; Dru | 1984 |
[Hydralazine in chronic heart failure].
Topics: Chronic Disease; Heart Failure; Hemodynamics; Humans; Hydralazine | 1984 |
Improved cardiac performance during exercise following hydralazine treatment in chronic heart failure.
Topics: Aged; Chronic Disease; Digoxin; Diuretics; Exercise Test; Heart Failure; Hemodynamics; Humans; Hydra | 1984 |
Adjuvant therapy of chronic refractory cardiac failure with oral hydralazine and isosorbide dinitrate.
Topics: Administration, Oral; Adolescent; Adult; Aged; Chronic Disease; Digoxin; Diuretics; Drug Therapy, Co | 1983 |
[Characteristics of the action of gemiton, adelfan and dopegit on cerebral circulation in arterial hypertension].
Topics: Aged; Antihypertensive Agents; Cerebrovascular Circulation; Cerebrovascular Disorders; Chronic Disea | 1984 |
[The changes in plasma catecholamine and hemodynamics in the treatment of chronic congestive heart failure with hydralazine].
Topics: Adult; Aged; Catecholamines; Chronic Disease; Female; Heart Failure; Hemodynamics; Humans; Hydralazi | 1984 |
A review of the long-term effects of prazosin and hydralazine in chronic congestive heart failure.
Topics: Chronic Disease; Drug Therapy, Combination; Follow-Up Studies; Heart Failure; Humans; Hydralazine; N | 1983 |
Oral hydralazine therapy for chronic mitral regurgitation in the dog.
Topics: Administration, Oral; Animals; Cardiac Output; Chronic Disease; Dog Diseases; Dogs; Female; Heart Ra | 1983 |
[Changes in the hemodynamic indices of hypertension patients].
Topics: Adult; Aged; Antihypertensive Agents; Chronic Disease; Drug Combinations; Drug Evaluation; Female; H | 1983 |
Use of hydralazine for intractable cardiac failure in childhood.
Topics: Antineoplastic Agents; Child; Chronic Disease; Female; Heart Failure; Humans; Hydralazine; Maxillary | 1980 |
Hydralazine in chronic CHF.
Topics: Administration, Oral; Aortic Valve Insufficiency; Cardiac Output; Chronic Disease; Drug Therapy, Com | 1981 |
Hemodynamic characterization of tolerance to long-term hydralazine therapy in severe chronic heart failure.
Topics: Adult; Blood Pressure; Chronic Disease; Drug Tolerance; Female; Heart Failure; Heart Rate; Hemodynam | 1982 |
Vasodilator treatment with isosorbide dinitrate and hydralazine in chronic heart failure.
Topics: Adult; Aged; Chronic Disease; Drug Therapy, Combination; Heart Failure; Hemodynamics; Humans; Hydral | 1981 |
Acute vasodilator therapy increases renal clearance of digoxin in patients with congestive heart failure.
Topics: Chronic Disease; Digoxin; Glomerular Filtration Rate; Heart Failure; Hemodynamics; Humans; Hydralazi | 1981 |
Dose requirements of hydralazine in patients with severe chronic congestive heart failure.
Topics: Adult; Aged; Blood Pressure; Chronic Disease; Dose-Response Relationship, Drug; Female; Heart Failur | 1980 |
Vasodilator therapy of chronic congestive heart failure.
Topics: Ambulatory Care; Chronic Disease; Heart Failure; Humans; Hydralazine; Nitrates; Prazosin; Quinazolin | 1980 |
Beneficial effects of hydralazine on rest and exercise hemodynamics in patients with chronic severe aortic insufficiency.
Topics: Adult; Aged; Aortic Valve Insufficiency; Blood Pressure; Chronic Disease; Exercise Test; Female; Hea | 1980 |
Importance of left ventricular chamber size in determining the response to hydralazine in severe chronic heart failure.
Topics: Administration, Oral; Adult; Aged; Blood Pressure; Cardiac Volume; Chronic Disease; Echocardiography | 1980 |
[Alteration in left ventricular function induced by dihydralazine in severe chronic congestive heart failure: limits of vasodilator therapy? (author's transl)].
Topics: Chronic Disease; Dihydralazine; Heart Diseases; Heart Ventricles; Hemodynamics; Humans; Hydralazine | 1980 |
Haemodynamic effects of hydralazine at rest and during exercise in patients with chronic heart failure.
Topics: Adult; Aged; Blood Pressure; Chronic Disease; Female; Heart Failure; Hemodynamics; Humans; Hydralazi | 1980 |
[Long-term treatment with quinapril in chronic aortic and mitral insufficiency].
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Aortic Valve Insufficiency; Chronic Disease; | 1995 |
[Individual approach to vasodilator treatment of pulmonary hypertension in chronic bronchitis].
Topics: Adult; Aminophylline; Bronchitis; Chronic Disease; Humans; Hydralazine; Hypertension, Pulmonary; Mid | 1994 |
Comparison of plasma aldosterone concentration among clinical status groups of dogs with chronic heart failure.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Captopril; | 1983 |
Long-term outpatient vasodilator therapy of congestive heart failure. Consideration of agents at rest and during exercise.
Topics: Chronic Disease; Drug Therapy, Combination; Heart Failure; Heart Ventricles; Hemodynamics; Humans; H | 1978 |
[Treatment of severe chronic cardiac insufficiency with dihydralazine. Short-and median-term results].
Topics: Administration, Oral; Adult; Aged; Chronic Disease; Dihydralazine; Drug Evaluation; Female; Heart Fa | 1979 |
[Hemodynamic effects of oral dihydralazine and sublingual isosorbide dinitrate, alone and in combination in chronic heart failure].
Topics: Administration, Oral; Aged; Chronic Disease; Dihydralazine; Drug Therapy, Combination; Female; Heart | 1979 |
Evaluation of a program of bed rest in the treatment of chronic hypertension in pregnancy.
Topics: Bed Rest; Birth Weight; Chronic Disease; Female; Fetal Death; Humans; Hydralazine; Hypertension; Inf | 1979 |
Antihypertensive treatment and pregnancy outcome in patients with mild chronic hypertension.
Topics: Adult; Antihypertensive Agents; Chronic Disease; Female; Fetal Growth Retardation; Fetus; Growth; Hu | 1979 |
Contributions of hemodynamic monitoring to the treatment of chronic congestive heart failure.
Topics: Chronic Disease; Dobutamine; Dopamine; Heart; Heart Failure; Hemodynamics; Humans; Hydralazine; Moni | 1979 |
Comparison of haemodynamic effects of oral hydralazine and prazosin hydrochloride in patients with chronic congestive heart failure.
Topics: Adult; Aged; Cardiac Output; Chronic Disease; Female; Heart Failure; Hemodynamics; Humans; Hydralazi | 1979 |
Comparison of haemodynamic effects of oral prazosin, oral hydralazine, and intravenous nitroprusside in same patients with chronic heart failure.
Topics: Adult; Aged; Chronic Disease; Ferricyanides; Heart Failure; Hemodynamics; Humans; Hydralazine; Male; | 1979 |
Combined clonidine and hydralazine therapy in severe and refractory hypertension.
Topics: Adult; Blood Pressure; Chronic Disease; Clonidine; Drug Evaluation; Drug Therapy, Combination; Femal | 1977 |
[The treatment of severe chronic cardiac failure by dihydralazine].
Topics: Adult; Aged; Chronic Disease; Dihydralazine; Heart Diseases; Humans; Hydralazine; Male; Middle Aged | 1978 |
Combination vasodilator therapy for severe chronic congestive heart failure.
Topics: Chronic Disease; Drug Therapy, Combination; Heart Failure; Hemodynamics; Humans; Hydralazine; Isosor | 1976 |
Oral hydralazine therapy for chronic refractory heart failure.
Topics: Adult; Aged; Blood Pressure; Capillaries; Chronic Disease; Female; Heart Failure; Heart Rate; Hemody | 1976 |
Therapy and prognosis of hypertension in chronic nephritis.
Topics: Adult; Aldosterone; Angiotensin II; Blood Volume; Catecholamines; Chronic Disease; Creatinine; Extra | 1975 |
The treatment of gestational hypertension.
Topics: Antihypertensive Agents; Chronic Disease; Diazoxide; Female; Humans; Hydralazine; Hypertension; Hype | 1975 |
Baroreceptor-mediated release of vasopressin in patients with chronic congestive heart failure and defective sympathetic responsiveness.
Topics: Adult; Aged; Cardiac Catheterization; Chronic Disease; Female; Heart Failure; Hemodynamics; Humans; | 1992 |
Does the magnitude of mitral regurgitation determine hemodynamic response to vasodilation in chronic congestive heart failure?
Topics: Adult; Aged; Chronic Disease; Heart Failure; Heart Valve Prosthesis; Hemodynamics; Humans; Hydralazi | 1991 |
Importance of venodilatation in prevention of left ventricular dilatation after chronic large myocardial infarction in rats: a comparison of captopril and hydralazine.
Topics: Animals; Blood Volume; Captopril; Chronic Disease; Heart; Heart Ventricles; Hydralazine; Male; Myoca | 1989 |
[Long-term vasodilator therapy of chronic refractory heart failure in patients with dilated cardiomyopathy].
Topics: Adult; Aged; Cardiomyopathy, Dilated; Chronic Disease; Drug Therapy, Combination; Echocardiography; | 1986 |
[Effect of hydralazine on bronchial patency and blood gas composition in patients with chronic obstructive bronchitis].
Topics: Adult; Bronchi; Bronchitis; Carbon Dioxide; Chronic Disease; Female; Humans; Hydralazine; Male; Midd | 1987 |
[Effect of hydralazine on the respiratory function of the lungs and blood gas composition in patients with chronic obstructive bronchitis].
Topics: Adult; Airway Obstruction; Bronchitis; Bronchodilator Agents; Carbon Dioxide; Chronic Disease; Femal | 1988 |
[Chronic drug-induced hepatitis caused by dihydralazine].
Topics: Aged; Biopsy, Needle; Chemical and Drug Induced Liver Injury; Chronic Disease; Dihydralazine; Female | 1988 |
[Effects of hydralazine therapy in patients with chronic congestive heart failure].
Topics: Adult; Chronic Disease; Female; Heart Failure; Hemodynamics; Humans; Hydralazine; Male; Middle Aged; | 1987 |
[Effect of peripheral vasodilators on thrombocyte aggregation in chronic circulatory insufficiency].
Topics: Adult; Aged; Chronic Disease; Drug Therapy, Combination; Female; Heart Failure; Humans; Hydralazine; | 1986 |
Comparative efficacy of digoxin, hydralazine and combination therapy in chronic congestive heart failure.
Topics: Adult; Chronic Disease; Digoxin; Drug Therapy, Combination; Female; Heart Failure; Humans; Hydralazi | 1986 |
[Regional hemodynamic function in chronic obstructive bronchitis with arterial hypertension].
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Bronchitis; Chronic Disease; Female; Hemodynamics; | 1986 |
[Long-term effects of digoxin and hydralazine in patients with chronic cardiac insufficiency].
Topics: Adult; Aged; Chronic Disease; Digoxin; Drug Administration Schedule; Drug Therapy, Combination; Fema | 1985 |
[Arterial hypertension in chronic bronchial obstruction and various problems of its treatment].
Topics: Adult; Asthma; Bronchitis; Chronic Disease; Drug Therapy, Combination; Female; Hemodynamics; Humans; | 1985 |
[Vasodilator agents in chronic asymptomatic aortic insufficiency: echocardiographic study].
Topics: Adult; Aged; Aortic Valve Insufficiency; Captopril; Chronic Disease; Echocardiography; Female; Hemod | 1985 |
When to intervene in chronic aortic regurgitation.
Topics: Aortic Valve Insufficiency; Chronic Disease; Echocardiography; Heart Ventricles; Humans; Hydralazine | 1986 |
Effect of vasodilators at rest and during exercise in young adults with cystic fibrosis and chronic cor pulmonale.
Topics: Adult; Chronic Disease; Cystic Fibrosis; Exercise Test; Female; Hemodynamics; Humans; Hydralazine; M | 1985 |
[Combined use of isoprenaline and hydralazine in the treatment of chronic circulatory insufficiency].
Topics: Adult; Cardiomyopathy, Dilated; Chronic Disease; Drug Therapy, Combination; Female; Heart Failure; H | 1985 |
[Role of dihydralazine in the treatment of chronic cardiac insufficiency].
Topics: Aged; Arterioles; Cardiac Output; Chronic Disease; Dihydralazine; Follow-Up Studies; Heart Failure; | 1985 |
Refractory hypertension.
Topics: Administration, Oral; Antihypertensive Agents; Chronic Disease; Diazoxide; Drug Combinations; Drug R | 1973 |
Control of renin release in experimental hypertension.
Topics: Acetylcholine; Animals; Arteries; Blood Flow Velocity; Blood Pressure; Catheterization; Chronic Dise | 1969 |
Hypertension in end-stage renal disease.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Black People; Blood Pressure; Body Weight; Chronic | 1969 |